Home / Business and Economy / Biotech Firm Metsera Doubles in Value After Analyst Upgrade
Biotech Firm Metsera Doubles in Value After Analyst Upgrade
9 Sep
Summary
- Metsera stock rises 5% after Leerink Partners initiates coverage with "outperform" rating
- Leerink sees Metsera's obesity drug platform as a key advantage over competitors
- Kingsoft Cloud jumps 13% on AI-driven growth and improving margins

In the latest market moves, several companies have seen significant stock price changes. Biotech firm Metsera rose 5% after Leerink Partners initiated coverage with an "outperform" rating, predicting the stock could double in value. Leerink cited Metsera's platform and pipeline of novel obesity-focused therapeutics as key advantages over competing assets.
Elsewhere, cloud provider Kingsoft Cloud jumped more than 13% after an upgrade to "buy" from Bank of America. The bank noted that AI is acting as a key growth driver for Kingsoft's public cloud services, contributing 39% of revenue in the second quarter of 2025. Improving margins were also cited as a positive factor.
Additionally, insurer Brighthouse Financial surged over 11% after reports that private equity firm Aquarian was in talks to raise funds for a potential takeover of the company.




